John D. Quisel, CEO of Disc Medicine, Inc. (NASDAQ:IRON), recently sold shares valued at over $806,000. The transactions, executed under a pre-established trading plan, involved selling 13,012 shares at a weighted average price range of $61.868 to $62.4107. The sale occurred as the $1.85 billion market cap company trades near $62.45, with analysts setting price targets between $70 and $118. According to InvestingPro analysis, the company maintains strong financial health with a current ratio of 19.36 and more cash than debt on its balance sheet. Following these sales, Quisel retains direct ownership of 72,065 shares. Additionally, Quisel acquired 23,012 shares through option exercises priced at $9.86 and $1.01 per share, respectively. The stock has shown strong momentum with a 40% gain over the past six months. For comprehensive insider trading analysis and 12 additional key insights about IRON, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Disc Medicine has seen significant developments in its clinical trials and operations. Jefferies maintained its Buy rating for Disc Medicine, with a price target of $111, citing positive data from an upcoming presentation of DISC-0974™. H.C. Wainwright also reiterated a Buy rating, increasing the price target to $118 due to promising developments with Disc Medicine’s drug candidates. Similarly, Scotiabank (TSX:BNS) upgraded its price target for Disc Medicine to $70, maintaining a Sector Outperform rating following positive feedback from the FDA on its phase 3 trial for bitopertin.
BMO Capital Markets increased the price target for Disc Medicine’s shares to $112, maintaining an Outperform rating, following a positive regulatory update for bitopertin. Meanwhile, Raymond (NS:RYMD) James upgraded Disc Medicine’s stock from Outperform to Strong Buy, setting a new price target of $110. These adjustments come after the company reported promising results from a Phase 1b study of DISC-0974 and announced a public stock offering of approximately $178 million to advance research and clinical development of its product candidates.
The company also welcomed new personnel, including Dr. Rahul Rajan Kaushik as Chief Technical Officer and Dr. Steve Caffé as Chief Regulatory Officer, both bringing over two decades of experience in the pharmaceutical industry. These recent developments reflect Disc Medicine’s continuous efforts to advance its clinical trials and operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.